oncology

Merck's Full Court Press On Oncology
Merck's Full Court Press On Oncology
Forbes
Merck
oncology
R&D
M&A
Tilos Therapeutics
Flag link:
Merck Bags Tilos, Adding an Immunotherapy Booster to Its Arsenal
Merck Bags Tilos, Adding an Immunotherapy Booster to Its Arsenal
Xconomy
Merck
M&A
Tilos Therapeutics
cancer immunotherapy
oncology
Flag link:
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
Fierce Pharma
Servier
oncology
Shire
M&A
Flag link:
ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads
ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads
Fierce Biotech
ASCO 2019
R&D
cancer
oncology
Flag link:
On the pulse of ASCO: pricing and clinical trial access
On the pulse of ASCO: pricing and clinical trial access
Pharmaforum
ASCO 2019
clinical trial access
clinical trials
oncology
drug pricing
Flag link:
FDA Approves First NDA Under Real-Time Oncology Review Pilot
FDA Approves First NDA Under Real-Time Oncology Review Pilot
RAPS.org
FDA
Novartis
oncology
Real Time Oncology Review
Piqray
Flag link:
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Fierce Pharma
Novartis
oncology
cancer
Saudi Arabia
Flag link:
Amgen, Syapse enter precision medicine collaboration in oncology
Amgen, Syapse enter precision medicine collaboration in oncology
Pharmaceutical Business Review
Amgen
Syapse
precision medicine
oncology
cancer
Flag link:
Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
BioCentury
FDA
ASCO
oncology
drug development
patients
clinical trials
tissue-agnostic drugs
Flag link:
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
BioSpace
Pfizer
Concerto HealthAI
oncology
real world data
real world evidence
Flag link:
Bristol-Myers Squibb and Concerto HealthAI Sign Cancer Real World Data Agreement
Bristol-Myers Squibb and Concerto HealthAI Sign Cancer Real World Data Agreement
BioSpace
Bristol-Myers Squibb
Concerto HealthAI
oncology
real world data
real world evidence
artificial intelligence
Flag link:
Early Stage Oncology Biotech Files for $100 Million IPO
Early Stage Oncology Biotech Files for $100 Million IPO
CP Wire
Turning Point Therapeutics
IPOs
oncology
Flag link:
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Fierce Biotech
Celgene
Exscientia
artificial intelligence
oncology
autoimmune disease
drug discovery
Flag link:
Life Science Investment Grew 50% 2018 over 2017 -- New JD Supra Life Sciences Report
Life Science Investment Grew 50% 2018 over 2017 -- New JD Supra Life Sciences Report
CP Wire
JD Supra
investment
devices
biotech
IPOs
oncology
Flag link:
Life Science Investment Grew 50% 2018 Over 2017 -- New JD Supra Life Sciences Report
JD Supra
investment
devices
biotech
IPOs
oncology
Flag link:
FDA looks to broaden cancer trial eligibility
FDA looks to broaden cancer trial eligibility
BioCentury
FDA
cancer
clinical trials
oncology
Flag link:
AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres
AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres
Endpoints
AstraZeneca
oncology
microbiome
Seres Therapeutics
Flag link:
Private oncology outfit Oncternal uses GTx as shell to make Nasdaq debut
Private oncology outfit Oncternal uses GTx as shell to make Nasdaq debut
Endpoints
Oncternal
GTx
NASDAQ
oncology
Flag link:
Gilead oncology chief departing to head up Glenmark spin-out
Gilead oncology chief departing to head up Glenmark spin-out
Biopharma Dive
oncology
Alessandro Riva
Gilead Sciences
Glenmark
Flag link:
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Fierce Pharma
M&A
oncology
neurology
Rare Diseases
Pfizer
Merck
JNJ
Biogen
Biomarin
Flag link:

Pages